Aiforia Technologies Plc – Managers' Transactions
Aiforia Technologies Plc, Company release, Managers’ Transactions, September 26, 2024 03:25 p.m. EEST
Aiforia Technologies Plc – Managers' Transactions
____________________________________________
Person subject to the notification requirement
Name: Tuomas Ropponen
Position: Other senior manager
Issuer: Aiforia Technologies Oyj
LEI: 743700TJRVBX7420Y723
Notification type: INITIAL NOTIFICATION
Reference number: 78984/5/4
____________________________________________
Transaction date: 2024-09-25
Outside a trading venue
Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT
Name of the instrument: Aiforia Technologies Oyj 2024 Options
Nature of transaction: ACCEPTANCE OF A STOCK OPTION
(X) Made under life insurance policy
Transaction details (1):
Volume: 25000 Unit price: 0 EUR
Aggregated transactions (1):
Volume: 25000 Volume weighted average price: 0 EUR
Further inquiries
Veli-Matti Parkkonen, CFO, Aiforia Technologies Plc
tel. +358405009878
https://investors.aiforia.com/
Certified Adviser
UB Corporate Finance Ltd
About Aiforia
Aiforia is a trusted provider of deep learning artificial intelligence (AI) solutions for pathology. Aiforia delivers software solutions that elevate diagnostic capabilities in image analysis, enabling remarkable medical discoveries now and in the future. With thousands of AI models already developed on the Aiforia platform for research use and several diagnostic solutions deployed, Aiforia is already significantly impacting pathology and healthcare.
Founded in 2013, Aiforia is a publicly traded company operating internationally with thousands of platform users across the globe. The company is headquartered in Helsinki, Finland, with offices in Cambridge, Massachusetts, and Rochester, Minnesota, and local representatives across Europe and North America. The diverse team at Aiforia includes experienced pathologists, medical scientists, AI and software developers, and a dedicated commercial team. Together, they are working to transform pathology with AI, enabling better care for each patient.
Find out more at www.aiforia.com